A clinical formulation indicated for Heart and Blood Pressure. Action centers on the regulation of coagulation factors, which assists with the prevention of harmful blood clots in the circulatory system.
Utilized to manage blood clotting risk by addressing liver protein synthesis to alleviate the danger of stroke and mitigate the recurrence of venous clots.
Mechanism of Action
Warfarin interferes with how the liver uses Vitamin K to produce clotting factors. By reducing the production of these proteins, it slows down the blood's ability to form clots, keeping blood flowing freely.
Route of Administration
Oral
Onset Time
24–72 hours
Duration
2–5 days after stopping
Contraindications
Active major bleeding, Hemorrhagic stroke, Uncontrolled hypertension, Pregnancy, Recent major surgery
Severe Adverse Events
Severe internal hemorrhage, Skin necrosis, Purple toe syndrome, Severe allergic reactions, Liver injury
Information for Warfarin is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
